FY2027 Earnings Forecast for Vaxart Issued By B. Riley

Vaxart, Inc. (NASDAQ:VXRT) – Analysts at B. Riley issued their FY2027 EPS estimates for Vaxart in a note issued to investors on Monday, November 18th. B. Riley analyst M. Mamtani anticipates that the biotechnology company will post earnings per share of $0.09 for the year. The consensus estimate for Vaxart’s current full-year earnings is ($0.43) per share. B. Riley also issued estimates for Vaxart’s FY2028 earnings at $0.13 EPS.

Separately, Oppenheimer assumed coverage on shares of Vaxart in a research note on Thursday, August 15th. They issued an “outperform” rating and a $4.00 target price for the company.

Vaxart Stock Performance

VXRT stock opened at $0.61 on Wednesday. The stock has a market cap of $107.84 million, a P/E ratio of -1.48 and a beta of 0.70. The firm has a 50 day simple moving average of $0.79 and a 200 day simple moving average of $0.77. Vaxart has a 52 week low of $0.52 and a 52 week high of $1.54.

Institutional Trading of Vaxart

Institutional investors have recently added to or reduced their stakes in the business. RA Capital Management L.P. acquired a new stake in shares of Vaxart in the first quarter worth $20,000,000. Millennium Management LLC lifted its stake in shares of Vaxart by 110.8% in the second quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock worth $2,660,000 after buying an additional 2,095,274 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Vaxart by 19.9% in the first quarter. Vanguard Group Inc. now owns 8,449,362 shares of the biotechnology company’s stock worth $10,984,000 after buying an additional 1,404,391 shares during the last quarter. Monaco Asset Management SAM acquired a new stake in shares of Vaxart in the second quarter worth $402,000. Finally, Geode Capital Management LLC lifted its stake in shares of Vaxart by 15.8% in the third quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company’s stock worth $2,160,000 after buying an additional 346,725 shares during the last quarter. 18.05% of the stock is currently owned by institutional investors and hedge funds.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.